Beijing Tong Ren Tang Chinese Medicine Valuation
Is 3613 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
1/6Valuation Score 1/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 3613 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 3613 (HK$8.47) is trading below our estimate of fair value (HK$10.05)
Significantly Below Fair Value: 3613 is trading below fair value, but not by a significant amount.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 3613?
Key metric: As 3613 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is 3613's PE Ratio? | |
|---|---|
| PE Ratio | 14.3x |
| Earnings | HK$494.14m |
| Market Cap | HK$7.09b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 4.1x |
| Enterprise Value/EBITDA | 9.8x |
| PEG Ratio | 0.9x |
Price to Earnings Ratio vs Peers
How does 3613's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 12.2x | ||
2186 Luye Pharma Group | 9.9x | 14.4% | HK$8.0b |
2877 China Shineway Pharmaceutical Group | 6.4x | 8.1% | HK$7.4b |
1666 Tong Ren Tang Technologies | 9.5x | -0.2% | HK$6.5b |
1349 Shanghai Fudan-Zhangjiang Bio-PharmaceuticalLtd | 23x | n/a | HK$6.8b |
3613 Beijing Tong Ren Tang Chinese Medicine | 14.3x | 16.5% | HK$7.1b |
Price-To-Earnings vs Peers: 3613 is expensive based on its Price-To-Earnings Ratio (14.3x) compared to the peer average (12.2x).
Price to Earnings Ratio vs Industry
How does 3613's PE Ratio compare vs other companies in the HK Pharmaceuticals Industry?
| 1 Company | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
858 Extrawell Pharmaceutical Holdings | 0.7x | n/a | US$14.77m |
| 1 Company | Estimated Growth | Market Cap |
|---|
Price-To-Earnings vs Industry: 3613 is expensive based on its Price-To-Earnings Ratio (14.3x) compared to the Hong Kong Pharmaceuticals industry average (8.4x).
Price to Earnings Ratio vs Fair Ratio
What is 3613's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 14.3x |
| Fair PE Ratio | 11.6x |
Price-To-Earnings vs Fair Ratio: 3613 is expensive based on its Price-To-Earnings Ratio (14.3x) compared to the estimated Fair Price-To-Earnings Ratio (11.6x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | HK$8.47 | HK$12.05 +42.3% | 6.2% | HK$12.80 | HK$11.30 | n/a | 2 |
| Dec ’25 | HK$8.23 | HK$12.05 +46.4% | 6.2% | HK$12.80 | HK$11.30 | n/a | 2 |
| Nov ’25 | HK$8.32 | HK$12.05 +44.8% | 6.2% | HK$12.80 | HK$11.30 | n/a | 2 |
| Oct ’25 | HK$9.21 | HK$12.05 +30.8% | 6.2% | HK$12.80 | HK$11.30 | n/a | 2 |
| Sep ’25 | HK$8.45 | HK$13.18 +55.9% | 2.5% | HK$13.50 | HK$12.85 | n/a | 2 |
| Aug ’25 | HK$8.53 | HK$13.18 +54.5% | 2.5% | HK$13.50 | HK$12.85 | n/a | 2 |
| Jul ’25 | HK$9.01 | HK$13.93 +54.6% | 7.7% | HK$15.00 | HK$12.85 | n/a | 2 |
| Jun ’25 | HK$9.57 | HK$13.93 +45.5% | 7.7% | HK$15.00 | HK$12.85 | n/a | 2 |
| May ’25 | HK$9.57 | HK$13.93 +45.5% | 7.7% | HK$15.00 | HK$12.85 | n/a | 2 |
| Apr ’25 | HK$8.95 | HK$13.93 +55.6% | 7.7% | HK$15.00 | HK$12.85 | n/a | 2 |
| Mar ’25 | HK$9.37 | HK$14.93 +59.3% | 13.9% | HK$17.00 | HK$12.85 | n/a | 2 |
| Feb ’25 | HK$9.63 | HK$14.93 +55.0% | 13.9% | HK$17.00 | HK$12.85 | n/a | 2 |
| Jan ’25 | HK$12.14 | HK$17.72 +45.9% | 5.7% | HK$18.55 | HK$16.30 | n/a | 3 |
| Dec ’24 | HK$12.80 | HK$17.72 +38.4% | 5.7% | HK$18.55 | HK$16.30 | HK$8.23 | 3 |
| Nov ’24 | HK$11.88 | HK$17.72 +49.1% | 5.7% | HK$18.55 | HK$16.30 | HK$8.32 | 3 |
| Oct ’24 | HK$12.96 | HK$17.72 +36.7% | 5.7% | HK$18.55 | HK$16.30 | HK$9.21 | 3 |
| Sep ’24 | HK$14.24 | HK$17.72 +24.4% | 5.7% | HK$18.55 | HK$16.30 | HK$8.45 | 3 |
| Aug ’24 | HK$13.80 | HK$17.32 +25.5% | 9.0% | HK$18.55 | HK$15.11 | HK$8.53 | 3 |
| Jul ’24 | HK$14.34 | HK$17.32 +20.8% | 9.0% | HK$18.55 | HK$15.11 | HK$9.01 | 3 |
| Jun ’24 | HK$14.52 | HK$15.56 +7.1% | 2.9% | HK$16.00 | HK$15.11 | HK$9.57 | 2 |
| May ’24 | HK$16.00 | HK$15.56 -2.8% | 2.9% | HK$16.00 | HK$15.11 | HK$9.57 | 2 |
| Apr ’24 | HK$13.52 | HK$15.56 +15.1% | 2.9% | HK$16.00 | HK$15.11 | HK$8.95 | 2 |
| Mar ’24 | HK$12.10 | HK$13.35 +10.3% | 6.4% | HK$14.20 | HK$12.50 | HK$9.37 | 2 |
| Feb ’24 | HK$12.22 | HK$13.35 +9.2% | 6.4% | HK$14.20 | HK$12.50 | HK$9.63 | 2 |
| Jan ’24 | HK$11.46 | HK$13.35 +16.5% | 6.4% | HK$14.20 | HK$12.50 | HK$12.14 | 2 |
| Dec ’23 | HK$10.54 | HK$13.35 +26.7% | 6.4% | HK$14.20 | HK$12.50 | HK$12.80 | 2 |
Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.
Discover undervalued companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/24 19:34 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Beijing Tong Ren Tang Chinese Medicine Company Limited is covered by 8 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yanyin Zhu | China International Capital Corporation Limited |
| null null | CMB International Securities Limited |
| Christina Chen | HSBC |